JOP20190176A1 - مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR) - Google Patents

مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)

Info

Publication number
JOP20190176A1
JOP20190176A1 JOJO/P/2019/0176A JOP20190176A JOP20190176A1 JO P20190176 A1 JOP20190176 A1 JO P20190176A1 JO P20190176 A JOP20190176 A JO P20190176A JO P20190176 A1 JOP20190176 A1 JO P20190176A1
Authority
JO
Jordan
Prior art keywords
ahr
modifiers
act
compounds
aryl hydrocarbon
Prior art date
Application number
JOJO/P/2019/0176A
Other languages
English (en)
Inventor
Michael Albers
Ulrich Deuschle
Christoph Steeneck
Thomas Hoffmann
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of JOP20190176A1 publication Critical patent/JOP20190176A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

غير متوفر
JOJO/P/2019/0176A 2017-02-01 2019-07-15 مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR) JOP20190176A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000157 2017-02-01
PCT/EP2018/052538 WO2018141855A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
JOP20190176A1 true JOP20190176A1 (ar) 2019-07-15

Family

ID=57960222

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2019/0176A JOP20190176A1 (ar) 2017-02-01 2019-07-15 مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)

Country Status (26)

Country Link
US (1) US11376241B2 (ar)
EP (1) EP3577115B1 (ar)
JP (1) JP2020505467A (ar)
KR (1) KR20190113902A (ar)
CN (1) CN110234650A (ar)
AR (1) AR110790A1 (ar)
AU (1) AU2018216955B2 (ar)
BR (1) BR112019015704A2 (ar)
CA (1) CA3051034A1 (ar)
CL (1) CL2019002112A1 (ar)
CO (1) CO2019007882A2 (ar)
CR (1) CR20190393A (ar)
CU (1) CU20190067A7 (ar)
EA (1) EA201991600A1 (ar)
EC (1) ECSP19055179A (ar)
IL (1) IL268082A (ar)
JO (1) JOP20190176A1 (ar)
MX (1) MX2019008993A (ar)
NI (1) NI201900075A (ar)
PE (1) PE20191479A1 (ar)
PH (1) PH12019550136A1 (ar)
SG (1) SG11201906959RA (ar)
TW (1) TWI674260B (ar)
UA (1) UA122746C2 (ar)
UY (1) UY37590A (ar)
WO (1) WO2018141855A1 (ar)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
US10815250B2 (en) 2018-02-06 2020-10-27 Ideaya Biosciences, Inc. AhR modulators
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
US12473262B2 (en) 2019-07-30 2025-11-18 Oregon State University Aryl hydrocarbon receptor activators
KR102351515B1 (ko) 2019-12-17 2022-01-14 (주)수파드엘릭사 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021148628A1 (en) * 2020-01-23 2021-07-29 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
JP2024500989A (ja) * 2020-12-28 2024-01-10 セルジーン コーポレーション 寄生虫症のためのヘテロ環化合物およびそれらの使用
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
US20260007652A1 (en) * 2022-10-14 2026-01-08 Oregon State University Selective Modulators of AhR-Regulated Transcription and Method for Using Such Modulators to Treat Cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (fr) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
RU2417226C2 (ru) 2005-11-18 2011-04-27 Ф.Хоффманн-Ля Рош Аг Производные азаиндол-2-карбоксамида
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
AU2010313622B2 (en) * 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EA035288B1 (ru) 2010-07-27 2020-05-25 Трастис Оф Бостон Юниверсити МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
EP2909172A1 (en) 2012-10-17 2015-08-26 F. Hoffmann-La Roche AG 6-aminoindole derivatives as trp channel antagonists
SMT201800230T1 (it) 2012-12-21 2018-07-17 Plexxikon Inc Composti e metodi per la modulazione della chinasi e loro indicazioni
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
US20210260045A1 (en) 2021-08-26
UA122746C2 (uk) 2020-12-28
ECSP19055179A (es) 2019-08-30
AU2018216955A1 (en) 2019-08-01
SG11201906959RA (en) 2019-08-27
CO2019007882A2 (es) 2019-10-09
CN110234650A (zh) 2019-09-13
UY37590A (es) 2018-02-28
CR20190393A (es) 2019-10-21
CL2019002112A1 (es) 2019-12-20
US11376241B2 (en) 2022-07-05
PE20191479A1 (es) 2019-10-16
KR20190113902A (ko) 2019-10-08
AU2018216955B2 (en) 2020-09-17
AR110790A1 (es) 2019-05-02
EA201991600A1 (ru) 2020-03-10
NI201900075A (es) 2019-10-30
TW201838991A (zh) 2018-11-01
EP3577115B1 (en) 2020-12-02
EP3577115A1 (en) 2019-12-11
MX2019008993A (es) 2019-12-19
JP2020505467A (ja) 2020-02-20
CA3051034A1 (en) 2018-08-09
BR112019015704A2 (pt) 2020-04-07
TWI674260B (zh) 2019-10-11
CU20190067A7 (es) 2020-03-04
WO2018141855A1 (en) 2018-08-09
IL268082A (en) 2019-09-26
PH12019550136A1 (en) 2020-03-02

Similar Documents

Publication Publication Date Title
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
MX378735B (es) Moduladores de receptores de quimiocina
IL268300A (en) Aryl hydrocarbon receptor (ahr) modulator compounds
CL2019001224A1 (es) Composiciones de células t con car anti--bcma.
MX2017001079A (es) Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
CL2018000947S1 (es) Automóvil
EA201891211A1 (ru) Ингибиторы cxcr2
ZA201904771B (en) Aryl hydrocarbon receptor (ahr) modulator compounds
CL2016001871A1 (es) Anticuerpos humanos para pd-1
GEAP201914379A (en) Heteroaryl compounds for kinase inhibition
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
IL268082A (en) Aryl hydrocarbon receptor modulatory compounds
SI3394094T1 (sl) T celični receptorji, specifični za NY-ESO-1 tumorski kompleks antigen-HLA-A*02
MX384883B (es) Métodos para usar activadores de piruvato cinasa.
MX372543B (es) Moduladores de receptor nuclear.
CL2018001940S1 (es) Automóvil
EP3595487A4 (en) BRACKET ARRANGEMENT FOR A WIRING HARNESS
CY1124413T1 (el) Ανταγωνιστες του υποδοχεα cgrp
CL2018000791S1 (es) Automóvil
MX2016015298A (es) Inhibidores de nampt y metodos.
JOP20200034B1 (ar) تركيبة للتنشيط المتحكم فيه للمبيض
BR112016028941A2 (pt) uso de antiespumantes como aditivos antideriva".
BR112018007282A2 (pt) métodos para síntese total de resolvina e1